Datapharm Australia

Executive Summary

Datapharm Australia is a well-established full-service contract research organization (CRO) founded in 1987, headquartered in Sydney. With a broad therapeutic portfolio spanning oncology, respiratory, cardiovascular, and over a dozen other areas, the company provides end-to-end clinical trial support including early-phase design, late-phase post-marketing studies, data capture, biostatistics, medical writing, pharmacovigilance, and regulatory services. Leveraging proprietary Project Advantage® tools and a strong network of clinical sites across Australia and New Zealand, Datapharm serves global pharmaceutical, biotechnology, and medical device sponsors. The company's long track record and comprehensive service offering position it as a reliable partner in the Asia-Pacific CRO market, though it faces competition from larger global CROs. With a private ownership structure and no disclosed funding rounds, Datapharm's growth trajectory is likely driven by steady contract wins and expansion of its service capabilities.

Upcoming Catalysts (preview)

• Q3 2026Major New Contract Win with Top-20 Pharma45% success
• Q4 2026Expansion of Service Offerings into Cell & Gene Therapy40% success
• TBDStrategic Partnership or Acquisition to Enhance Digital Health Capabilities35% success